COO Cooper Companies (COO) Insider Trading, Ownership & Congress Trades
Medical Devices · Ophthalmic goods · CIK 0000711404
Cluster · 3 insidersCongress · 1
Funds added, last quarter
0
13F, latest reported quarter
What the filings say about COO
Insiders, 180 days
+$1.9M net bought
3 buyers
Congress, 1 year
1 bought · 0 sold
Latest: purchase, 2026-06-05
Cooper Companies insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, COOPER COMPANIES, INC. insiders bought a net $1.9M of stock across 75 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Sep 14, 2026.
- +4.4% median (+4.4% mean) 90-day return after 2 previous buys.
- The trade is 32.2% of the 31,099 shares held after it.
- 2 other insiders bought within 30 days.
Insider activity: Director Kurzius Lawrence Erik bought about $549.3K of COO on Sep 16, 2026; 2 other insiders bought within 30 days.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Dec 17, 2025.
- +4.4% median (+4.4% mean) 90-day return after 2 previous buys.
- The trade is 47.4% of the 21,099 shares held after it.
- 2 other insiders bought within 30 days.
Insider activity: Director Kurzius Lawrence Erik bought about $539.1K of COO on Sep 14, 2026; 2 other insiders bought within 30 days.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Sep 11, 2026.
- The trade is 15.0% of the 20,000 shares held after it.
- 2 other insiders bought within 30 days.
Insider activity: Director Rosebrough Walter M Jr bought about $162.9K of COO on Sep 14, 2026; 2 other insiders bought within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 100.0% of the 4,701 shares held after it.
- 2 other insiders bought within 30 days.
Insider activity: Director Keel Paul A bought about $250.0K of COO on Sep 11, 2026; 2 other insiders bought within 30 days.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 41.2% of the 17,000 shares held after it.
- 2 other insiders bought within 30 days.
Insider activity: Director Rosebrough Walter M Jr bought about $378.8K of COO on Sep 11, 2026; 2 other insiders bought within 30 days.75 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$1.9M over 180 days
+$1.9M over 90 days
more than 95% of Medical Devices
Congress
1 member bought in the last year
the lowest in Medical Devices
Funds
under five funds report holding it
Revenue
+5.1% year over year
below 66% of Medical Devices
Margin
9.2% net margin
more than 81% of Medical Devices
Buybacks
$447.2M repurchased, FY to 2026-07-31
more than 85% of Medical Devices
Short interest
4.4% of the float short (float per yahoo 2026-10-26) · 1.6 days to cover · settled 2026-09-30
more than 59% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch COO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-18.0%12M
Insider buy
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns COO: institutional holders (13F)
13F holdings, latest reported quarter
SEC 13F
No reported 13F holders
No fund above the reporting threshold listed this stock last quarter. That is a fact, not missing data.
Congress trades in COO
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Bought 2026-06-05 · disclosed 27 days later
$1,001 - $15,000
Bought 2026-05-29 · disclosed 10 days later
$1,001 - $15,000
Bought 2025-12-10 · disclosed 33 days later
$1,001 - $15,000
Sold 2025-05-15 · disclosed 25 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
COO planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
Executive pay vs shareholder return · Mr. White
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$16.1M
$1.8M
$4.1M
-33%
+4%
2024
$15.4M
$39.8M
$3.8M
+0%
-2%
2023
$13.5M
$22.3M
$3.5M
-25%
-25%
2022
$11.7M
-$9.2M
$3.1M
-34%
-23%
2021
$11.0M
$36.2M
$2.8M
+0%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $1.9M bought by insiders over 180 days, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
COO financials
Revenue growth
+5.1%
XBRL, annual
Net margin
9.2%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$4.2B
four quarters, 2025-08-01 to 2026-07-31
Revenue, TTM COO
| FY Oct 2025 | $4.1B |
| FY Oct 2024 | $3.9B |
| FY Oct 2023 | $3.6B |
| FY Oct 2022 | $3.3B |
| FY Oct 2021 | $2.9B |
| Jul 2026 | $1.1B |
| Apr 2026 | $1.1B |
| Jan 2026 | $1.0B |
| Oct 2025 | $1.1B |
| Jul 2025 | $1.1B |
| Apr 2025 | $1.0B |
| Jan 2025 | $964.7M |
| Oct 2024 | $1.0B |
At each fiscal year end
Single quarter
Net margin, TTM
+13.5%
net income over revenue, 2025-08-01 to 2026-07-31
Net margin, TTM COO
| FY Oct 2025 | +9.2% |
| FY Oct 2024 | +10.1% |
| FY Oct 2023 | +8.2% |
| FY Oct 2022 | +11.7% |
| FY Oct 2021 | +100.8% |
| Jul 2026 | +40.6% |
| Apr 2026 | -7.2% |
| Jan 2026 | +12.8% |
| Oct 2025 | +7.9% |
| Jul 2025 | +9.3% |
| Apr 2025 | +8.7% |
| Jan 2025 | +10.8% |
| Oct 2024 | +11.5% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$678.0M
operating cash flow minus capex, 2025-08-01 to 2026-07-31
Free cash flow, TTM COO
| FY Oct 2025 | $433.7M |
| FY Oct 2024 | $288.1M |
| FY Oct 2023 | $215.0M |
| FY Oct 2022 | $450.4M |
| FY Oct 2021 | $524.2M |
| Jul 2026 | $273.0M |
| Apr 2026 | $96.4M |
| Jan 2026 | $158.7M |
| Oct 2025 | $149.9M |
| Jul 2025 | $164.5M |
| Apr 2025 | $18.1M |
| Jan 2025 | $101.2M |
| Oct 2024 | $128.1M |
At each fiscal year end
Single quarter
Debt to equity
0.31x
long-term 2026-07-31 plus current 2026-07-31; equity 2026-07-31
Debt to equity COO
| FY Oct 2025 | 0.30x |
| FY Oct 2024 | 0.32x |
| FY Oct 2023 | 0.34x |
| FY Oct 2022 | 0.38x |
| FY Oct 2021 | 0.21x |
| Jul 2026 | 0.31x |
| Apr 2026 | 0.30x |
| Jan 2026 | 0.30x |
| Oct 2025 | 0.30x |
| Jul 2025 | 0.30x |
| Apr 2025 | 0.31x |
| Jan 2025 | 0.31x |
| Oct 2024 | 0.32x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.41x
TTM operating cash flow over long-term 2026-07-31 plus current 2026-07-31
Cash flow to debt COO
| FY Oct 2025 | 0.32x |
| FY Oct 2024 | 0.27x |
| FY Oct 2023 | 0.24x |
| FY Oct 2022 | 0.25x |
| FY Oct 2021 | 0.50x |
| Jul 2026 | 0.41x |
| Apr 2026 | 0.39x |
| Jan 2026 | 0.35x |
| Oct 2025 | 0.32x |
| Jul 2025 | 0.33x |
| Apr 2025 | 0.30x |
| Jan 2025 | 0.31x |
| Oct 2024 | 0.27x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+6.8%
TTM net income over average of 2025-07-31 and 2026-07-31
Return on equity COO
| FY Oct 2025 | +4.6% |
| FY Oct 2024 | +5.0% |
| FY Oct 2023 | +4.0% |
| FY Oct 2022 | +5.5% |
| FY Oct 2021 | +54.7% |
| Jul 2026 | +6.8% |
| Apr 2026 | +2.9% |
| Jan 2026 | +4.9% |
| Oct 2025 | +4.6% |
| Jul 2025 | +5.0% |
| Apr 2025 | +5.1% |
| Jan 2025 | +5.3% |
| Oct 2024 | +5.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+4.6%
TTM net income over average of 2025-07-31 and 2026-07-31
Return on assets COO
| FY Oct 2025 | +3.0% |
| FY Oct 2024 | +3.3% |
| FY Oct 2023 | +2.5% |
| FY Oct 2022 | +3.7% |
| FY Oct 2021 | +36.0% |
| Jul 2026 | +4.6% |
| Apr 2026 | +1.9% |
| Jan 2026 | +3.3% |
| Oct 2025 | +3.0% |
| Jul 2025 | +3.3% |
| Apr 2025 | +3.4% |
| Jan 2025 | +3.4% |
| Oct 2024 | +3.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
effective tax rate -23%, not meaningful
Return on invested capital COO
| FY Oct 2025 | +4.3% |
| FY Oct 2024 | +4.6% |
| FY Oct 2023 | +3.9% |
| FY Oct 2022 | +4.2% |
| FY Oct 2021 | n/a |
| Jul 2026 | n/a |
| Apr 2026 | +2.7% |
| Jan 2026 | +4.5% |
| Oct 2025 | +4.3% |
| Jul 2025 | +4.7% |
| Apr 2025 | +4.7% |
| Jan 2025 | +4.8% |
| Oct 2024 | +4.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+4.9%
operating income (EBIT proxy) over average of 2025-07-31 and 2026-07-31 minus current liabilities
Return on capital employed COO
| FY Oct 2025 | +6.1% |
| FY Oct 2024 | +6.4% |
| FY Oct 2023 | +5.1% |
| FY Oct 2022 | +5.3% |
| FY Oct 2021 | +6.9% |
| Jul 2026 | +4.9% |
| Apr 2026 | +4.5% |
| Jan 2026 | +6.5% |
| Oct 2025 | +6.1% |
| Jul 2025 | +6.6% |
| Apr 2025 | +6.7% |
| Jan 2025 | +6.6% |
| Oct 2024 | +6.4% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
20.94x
close 2026-10-26 over four quarters of diluted EPS, 2025-08-01 to 2026-07-31
P/E, trailing COO
| FY Oct 2025 | 37.39x |
| FY Oct 2024 | 53.41x |
| FY Oct 2023 | 52.31x |
| FY Oct 2022 | 35.23x |
| FY Oct 2021 | 1.76x |
| Jul 2026 | 24.77x |
| Apr 2026 | 53.76x |
| Jan 2026 | 40.49x |
| Oct 2025 | 37.39x |
| Jul 2025 | 34.65x |
| Apr 2025 | 39.45x |
| Jan 2025 | 46.64x |
| Oct 2024 | 53.41x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$14.0B
market value at close 2026-10-26 on 2026-09-03 shares, plus long-term 2026-07-31 plus current 2026-07-31, minus cash 2026-07-31
Enterprise value COO
| FY Oct 2025 | $16.3B |
| FY Oct 2024 | $23.3B |
| FY Oct 2023 | $6.3B |
| FY Oct 2022 | $6.0B |
| FY Oct 2021 | $6.5B |
| Jul 2026 | $16.5B |
| Apr 2026 | $14.6B |
| Jan 2026 | $18.3B |
| Oct 2025 | $16.3B |
| Jul 2025 | $16.5B |
| Apr 2025 | $18.8B |
| Jan 2025 | $21.7B |
| Oct 2024 | $23.3B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield COO
| FY Oct 2025 | +3.1% |
| FY Oct 2024 | +1.4% |
| FY Oct 2023 | +5.6% |
| FY Oct 2022 | +13.4% |
| FY Oct 2021 | +10.2% |
| Jul 2026 | +4.8% |
| Apr 2026 | +4.6% |
| Jan 2026 | +3.1% |
| Oct 2025 | +3.1% |
| Jul 2025 | +2.9% |
| Apr 2025 | +2.2% |
| Jan 2025 | +2.0% |
| Oct 2024 | +1.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.49x
P/E over trailing EPS growth of 43%: four quarters to 2026-07-31 against the four to 2025-07-31
PEG, trailing COO
| FY Oct 2025 | n/a |
| FY Oct 2024 | 1.69x |
| FY Oct 2023 | n/a |
| FY Oct 2022 | n/a |
| FY Oct 2021 | 0.00x |
| Jul 2026 | 0.57x |
| Apr 2026 | n/a |
| Jan 2026 | n/a |
| Oct 2025 | n/a |
| Jul 2025 | 2.60x |
| Apr 2025 | 1.87x |
| Jan 2025 | 1.14x |
| Oct 2024 | 1.69x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-10 | 2024-10 | 2023-10 | 2022-10 | |
|---|---|---|---|---|
| Revenue | $4.1B | $3.9B | $3.6B | $3.3B |
| Gross profit | $2.7B | $2.6B | $2.4B | $2.1B |
| Operating income | $682.9M | $705.7M | $533.1M | $507.6M |
| Net income | $374.9M | $392.3M | $294.2M | $385.8M |
| EPS (diluted) | 1.87 | 1.96 | 1.48 | 1.94 |
| Operating cash flow | $796.1M | $709.3M | $607.5M | $692.4M |
| Cash | $110.6M | $107.6M | $120.8M | $138.2M |
| Long-term debt | $2.5B | $2.5B | $2.5B | $2.3B |
| Buybacks | $290.1M | $0 | $0 | $78.5M |
| Dividends paid | $0 | $0 | $3.0M | $3.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
COO Stock Sonar score 6/7 axes
Find similar shapesCompareCOO ranks highest on insider conviction (90th percentile) and risk and compliance (80th), and lowest on growth (34th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
COO filings, in plain words
Are Cooper Companies insiders buying or selling COO?
In the 180 days to 2026-10-28, Cooper Companies insiders were net buyers, a net $1.9M across purchases and sales reported on Form 4, by 3 buyers.
Have members of Congress traded COO?
Yes. In the year to 2026-10-28, 1 House member disclosed buying COO and 0 House members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-06-05.
Read the full summary
In the 180 days to 2026-10-28, Cooper Companies insiders were net buyers of COO, a net $1.9M across purchases and sales reported on Form 4 by 3 buyers. 3 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. In the year to 2026-10-28, 1 member of Congress disclosed buying COO and 0 members disclosed selling it; the latest on record is a purchase by Gilbert Cisneros dated 2026-06-05. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
